PROCESS FOR PREPARING A COUMARIN-CAGED FORSKOLIN DERIVATIVE, FORSKOLIN DERIVATIVE AND USE OF SAID FORSKOLIN DERIVATIVE

Abstract

A process for preparing coumarin-caged forskolin derivatives, the forskolin derivatives themselves and to uses of the same.

Claims

1. A process for preparing a coumarin-caged forskolin derivative (1) of formula ##STR00025## comprising the steps of: a. synthesizing (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl methyl(2-(2,2,2-trifluoroacetamido)ethyl)carbamate (4) of formula ##STR00026## by a first carbamoylation of 2,2,2-trifluoro-N-(2-methylamino-ethyl)-acetamide 5 and 6-bromo-7-methoxymethoxy coumarin-4-ylmethyl 4′-nitrophenyl carbonate 6, b. synthesizing (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-aminoethyl)(methyl)carbamate (3) of formula ##STR00027## by a first deprotection of (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl methyl(2-(2,2,2-trifluoroacetamido)ethyl)carbamate 4, c. synthesizing (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-(((((2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-6-(dimethylamino)-12-hydroxy-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′: 1,2]naphtho[1,8-de][1,3]dioxin-11-yl)oxy)carbonyl)amino)ethyl)(methyl)carbamate (7) of formula ##STR00028## by a second carbamoylation of 7-deacetyl forskolin-6,7-carbonate 1,9-dimethylformamide dimethyl acetal 2 and (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-aminoethyl)(methyl)carbamate 3, d. synthesizing (2R,4aR,4a1R,6S,10aS,11 S,12 S,12aR)-11-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-6-(dimethylamino)-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H, 8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-12-yl acetate (8) of formula ##STR00029## by acetylation of (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-(((((2R,4aR,4a1R,6S,10aS,11 S,12S,12aR)-6-(dimethylamino)-12-hydroxy-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′: 1,2]naphtho[1,8-de][1,3]dioxin-11-yl)oxy)carbonyl)amino)ethyl)(methyl)carbamate 7, e. synthesizing (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate (9) of formula ##STR00030## by a second deprotection of (2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-11-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-6-(dimethylamino)-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-12-yl acetate 8, f. synthesizing (3R,4aR,5 S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-hydroxy-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3 4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate (1) of formula ##STR00031## by a third deprotection of (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate 9.

2. The process according to claim 1, characterized in that the first carbamoylation according to step a. is carried out with a polar aprotic solvent between approximately 10° C. and 30° C.

3. The process according to claim 1, characterized in that the first deprotection according to step b. is carried out with a base and an aqueous alkanolic solvent between approximately 10° C. and 30° C.

4. The process according to claim 1, characterized in that the second carbamoylation according to step c. is carried out with a polar aprotic solvent, a catalyst and an auxiliary base between approximately 0° C. and 10° C.

5. The process according to claim 1, characterized in that the acetylation according to step d. is carried out with a polar aprotic solvent and an acetylation reagent between approximately 0° C. and 10° C.

6. The process according to claim 1, characterized in that the second deprotection according to step e. is carried out with an organic acid and an alkanol between approximately 10° C. and 30° C.

7. The process according to claim 1, characterized in that the third deprotection according to step f. is carried out with a catalyst and with a non-polar aprotic solvent between approximately 10° C. and 30° C.

8. The process according to claim 1, characterized in that in step a., instead of (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl methyl(2-(2,2,2-trifluoroacetamido)ethyl)carbamate 4 to prepare JCF 1, the general educt (pseudo)halogen-(methoxymethoxy-2-oxo-2H-chromen-4-yl)methyl methyl(2-(2,2,2-trifluoroacetamido)alkyl)carbamate of formula ##STR00032## wherein n is=1-5; R.sup.1 is=OH; and R.sup.2 is=F, Cl, Br, I, CN, —N.sub.3, —OCN, —NCO, —CNO, —SCN, —NCS, or —SeCN, is synthesized from 2,2,2-trifluoro-N-(2-methylamino alkyl)-acetamide and (pseudohalogen)-methoxymethoxy coumarin-4-ylmethyl 4′-nitrophenyl carbonate to prepare a coumarin-caged forskolin derivative according to the general formula ##STR00033## wherein n is=1-5; R.sup.1 is=OH; and R.sup.2 is=F, Cl, Br, I, CN, —N.sub.3, —OCN, —NCO, —CNO, —SCN, —NCS, or —SeCN.

9. A coumarin-caged forskolin derivative of formula ##STR00034## wherein n is=1-5; R.sup.1 is=OH; and R.sup.2 is=F, Cl, Br, I, CN, —N.sub.3, —OCN, —NCO, —CNO, —SCN, —NCS, or —SeCN.

10. The coumarin-caged forskolin derivative of claim 9, wherein the derivative is (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-hydroxy-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate (1) of formula: ##STR00035##

11. 6-Bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-aminoethyl)(methyl)carbamate 3 of formula ##STR00036##

12-14. (canceled)

15. The coumarin-caged forskolin derivative of claim 9, wherein the derivative is (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate (9) of formula ##STR00037##

16. A method of irradiating the coumarin-caged forskolin derivative of claim 9 with light in a photolysis process, wherein the derivative is cleaved after irradiation with light in a photolysis process to form forskolin carbamate 10, CO.sub.2 and the corresponding methylcoumarin derivative.

17. A method of increasing cAMP concentration and Ca.sub.2.sup.+ concentration in cell- and tissue-based samples, comprising introducing the coumarin-caged forskolin derivative of claim 9 into a cell or tissue, and irradiating the coumarin-caged forskolin derivative with light in a photolysis process.

18. The method of claim 16, characterized in that the coumarin-caged forskolin derivative is introduced into a cell or tissue prior to irradiation, and, after irradiation, the increase in the intracellular Ca.sup.2+ concentration resulting from the increase in the cAMP concentration is measured with a fluorescence-based detection process.

19. A method of irradiating the coumarin-caged forskolin derivative of claim 10 with light in a photolysis process, wherein the derivative is cleaved after irradiation with light in a photolysis process to form forskolin carbamate 10, CO.sub.2 and the corresponding methylcoumarin derivative.

20. The method of claim 17, characterized in that the increase in the intracellular Ca.sup.2+ concentration resulting from the increase in the cAMP concentration is measured with a fluorescence-based detection process.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] FIG. 1: Forskolin and NKH 477.

[0015] FIG. 2: Synthesis overview of JCF 1 consisting of protected forskolin 2 and a coumarin derivative 3 functionalized with N-methylethylenediamine.

[0016] FIG. 3: Synthesis of (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl methyl(2-(2,2,2-trifluoroacetamido)ethyl)carbamate 4 (step a.).

[0017] FIG. 4: Synthesis of (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl(2-aminoethyl)(methyl)carbamate 3 (step b.).

[0018] FIG. 5: Synthesis of (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl(2-(((((2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-6-(dimethylamino)-12-hydroxy-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-11-yl)oxy)carbonyl)amino)ethyl)(methyl)carbamate 7 (step c.).

[0019] FIG. 6: Synthesis of (2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-11-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-6-(dimethylamino)-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-12-ylacetate 8 (step d.).

[0020] FIG. 7: Synthesis of (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate 9 (step e.).

[0021] FIG. 8: Synthesis of (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-hydroxy-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate, (JCF 1) (step f.).

[0022] FIG. 9: Photolysis of JCF 1

[0023] FIG. 10: Irradiation of JCF 1 and cleavage to form forskolin carbamate 10

[0024] FIG. 11: Relative fluorescence when loaded with 10 μM JCF 1; the time points were measured at an interval of 1 min.

[0025] FIG. 12: Relative fluorescence when loaded with 30 μM JCF 1; the time points were measured at an interval of 1 min.

[0026] FIG. 13: Relative fluorescence when loaded with 10 μM NHK 477; the time points were measured at an interval of 1 min.

[0027] FIG. 14: Relative fluorescence when loaded with 30 μM NHK 477; the time points were measured at an interval of 1 min.

[0028] FIG. 15: Relative fluorescence without loading (negative control); the time points were measured at an interval of 1 min.

DETAILED DESCRIPTION

[0029] In an embodiment, the present invention provides a process for preparing “coumarin-caged forskolin derivatives”. Furthermore, the present invention provides in another embodiment the corresponding coumarin-caged forskolin derivatives in order to be able to conduct cell- or tissue-based investigations.

[0030] According to an embodiment of the present invention, a process is provided for preparing a specific coumarin-caged forskolin derivative JCF 1 of formula

##STR00008##

[0031] is characterized by the steps of:

a. synthesizing ((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl methyl(2-(2,2,2-trifluoroacetamido)ethyl)carbamate 4 of formula

##STR00009##

by a first carbamoylation of 2,2,2-trifluoro-N-(2-methylamino-ethyl)-acetamide 5 and 6-bromo-7-methoxymethoxy coumarin-4-ylmethyl 4′-nitrophenyl carbonate 6 (FIG. 3),
b. synthesizing (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-aminoethyl)(methyl)carbamate 3 of formula

##STR00010##

by a first deprotection of (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl methyl(2-(2,2,2-trifluoroacetamido)ethyl)carbamate 4 (FIG. 4),
c. synthesizing (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-(((((2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-6-(dimethylamino)-12-hydroxy-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-11-yl)oxy)carbonyl)amino)ethyl)(methyl)carbamate 7 according to the formula

##STR00011##

by a second carbamoylation of 7-deacetyl forskolin-6,7-carbonate 1,9-dimethylformamide dimethyl acetal 2 and (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-aminoethyl)(methyl)carbamate 3 (FIG. 5),
d. synthesizing (2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-11-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-6-(dimethylamino)-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-12-yl acetate 8 according to the formula

##STR00012##

by acetylation of (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-(((((2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-6-(dimethylamino)-12-hydroxy-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-11-yl)oxy)carbonyl)amino)ethyl)(methyl)carbamate 7 (FIG. 6),
e. synthesizing (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate 9 according to the formula

##STR00013##

by a second deprotection of (2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-11-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-6-(dimethylamino)-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-12-yl acetate 8 (FIG. 7),
f. synthesizing (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-hydroxy-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-ylacetate (JCF 1) according to the formula

##STR00014##

by a third deprotection of (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-ylacetate 9 (FIG. 8).

[0032] The other excipients of steps a. to f. can advantageously correspond to those of the exemplary embodiment.

[0033] In one embodiment of the invention, the first carbamoylation according to step a (FIG. 3) can be carried out with a polar aprotic solvent, for example dimethylformamide (DMF), N-methylformamide (NMF), tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), acetonitrile (ACN), dimethylpropyleneurea (DMPU), pyridine, acetone between approximately 10° C. and 30° C.

[0034] In a further embodiment of the invention, the first deprotection according to step b. (FIG. 4) can be carried out with a mineral base and an aqueous alkanolic solvent between approximately 10° C. and 30° C.

[0035] The second carbamoylation according to step c. (FIG. 5) can advantageously be carried out with a polar aprotic solvent, e.g., dimethylformamide (DMF), N-methylformamide (NMF), tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), acetonitrile (ACN), dimethylpropyleneurea (DMPU), pyridine, acetone, and an auxiliary base, e.g., diazabicycloundecene (DBU), triethylamine (Et3N), diisopropylethylamine (DIEA), N-methylmorpholine (NMM), tributylamine, and, for example, a catalyst, e.g., py*HCl, with the exclusion of light between approximately 0° C. and 10° C.

[0036] The acetylation according to step d. (FIG. 6) can be carried out with a polar aprotic solvent, e.g., dimethylformamide (DMF), N-methylformamide (NMF), tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), acetonitrile (ACN), dimethylpropyleneurea (DMPU), pyridine, acetone, and an acetylation reagent, e.g., acetyl chloride, acetic anhydride, and with the exclusion of light between approximately 0° C. and 10° C.

[0037] The second deprotection according to step e. (FIG. 7) can be carried out with an organic acid, for example formic acid, acetic acid, propionic acid, and so on, and any alkanol, for example methanol, ethanol, and so on, between approximately 10° C. and 30° C.

[0038] The third deprotection according to step f. (FIG. 8) can be carried out, for example, with a mild catalyst, such as NaHSO.sub.4*SiO.sub.2 in a non-polar aprotic solvent, e.g., CH.sub.2Cl.sub.2, benzene, ether, and so on and between approximately 10° C. and 30° C.

[0039] According to an embodiment of the invention, the coumarin-caged forskolin derivative (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-hydroxy-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate (JCF 1) according to the formula:

##STR00015##

is claimed.

[0040] The following intermediates are advantageously provided for the first time during the process according to embodiments of the invention:

(6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-aminoethyl)(methyl)carbamate 3 according to the formula

##STR00016##

and (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl methyl(2-(2,2,2-trifluoroacetamido)ethyl)carbamate 4 according to the formula

##STR00017##

and (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-(((((2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-6-(dimethylamino)-12-hydroxy-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-11-yl)oxy)carbonyl)amino)ethyl)(methyl)carbamate 7 according to the formula

##STR00018##

and also (2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-11-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-6-(dimethylamino)-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-12-yl acetate 8 according to the formula

##STR00019##

and also (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate 9 according to the formula

##STR00020##

General Synthesis Description

[0041] According to an embodiment of the invention, caged forskolin derivatives for photolysis in cells and tissues with a resulting increase in the cAMP concentration are synthesized in six steps a. to f.

[0042] Prior to the coupling of the protected forskolin 2 (FIG. 2 and FIG. 5) to the coumarin cage 3 or its analogs (see FIG. 5), a first carbamoylation of a (pseudo-)halogen-substituted protected coumarin is carried out (analogously to FIG. 3) in order to insert an N-methylalkylenediamine function there. For this purpose, a nitrophenyl carbonate of the protected (pseudo-)halogen-substituted 4-hydroxymethyl coumarin 6 or its analogs is reacted with trifluoro-N-(2-(methylamino)alkyl)acetamide 5 or its analogs. The trifluoroacetyl group is subsequently cleaved off (first deprotection, analogous to FIG. 4).

[0043] The amine 3 formed in the process (or its analogs) is coupled in the next step to the completely protected forskolin carbonate 2 by a second carbamoylation (analogously to FIG. 5). The coupled product 7 (or its analogs) is acetylated to the forskolin (acetylation analogous to FIG. 6) and is completely deprotected in two further steps to form the caged forskolin JCF 1 or its analogs (second and third deprotection, analogous to FIGS. 7 and 8).

[0044] By means of the aforementioned process steps according to embodiments of the invention, the coumarin-caged forskolin derivatives according to embodiments of the invention according to the general formula

##STR00021##

n=1-5; R.sup.1=OH; R.sup.2=F, Cl, Br, I, CN, —N3, —OCN, —NCO, —CNO, —SCN, —NCS, —SeCN
are provided particularly advantageously. These are suitable for the use according to further embodiments of the invention.

[0045] It is self-evident that for this purpose the educts for the preparation of JCF 1 analogs as described must be adapted accordingly except for the completely protected forskolin 2.

[0046] For this purpose, in an embodiment, instead of the specific educt 4 of formula

##STR00022##

the general educt (pseudo)halogen-(methoxymethoxy-2-oxo-2H-chromen-4-yl)methyl methyl(2-(2,2,2-trifluoroacetamido)alkyl)carbamate of formula

##STR00023##

n=1-5; R.sup.1=OH; R.sup.2=F, Cl, Br, I, CN, —N.sub.3, —OCN, —NCO, —CNO, —SCN, —NCS, —SeCN
is synthesized in step a. (analogous to FIG. 3) of claim 1 from 2,2,2-trifluoro-N-(2-methylamino alkyl)-acetamide and (pseudohalogen)-methoxymethoxy coumarin-4-ylmethyl 4′-nitrophenyl carbonate to provide the coumarin-caged forskolin derivatives according to the general formula.

[0047] Step a. of claim 1 is then as follows for the general synthesis process:

##STR00024##

n=1-5; R.sup.1=OH; R.sup.2=F, Cl, Br, I, CN, —N.sub.3, —OCN, —NCO, —CNO, —SCN, —NCS, —SeCN

[0048] With regard to the process parameters, the further synthesis route of these derivatives corresponds to that of the process for preparing JCF 1.

[0049] JCF 1 (or its analogs provided according to the invention) is cleaved after irradiation with light in a photolysis process to form forskolin-(2-(methylamino)ethyl)carbamate 10 (or its homologs), CO.sub.2 and the corresponding methylcoumarin derivative (FIG. 9). The remaining coumarin-caged forskolin derivatives according to the invention are cleaved analogously to form the homologous forskolin carbamates, CO.sub.2 and the corresponding methylcoumarin derivatives.

[0050] This advantageously allows the use of the coumarin-caged forskolin derivatives according to embodiments of the invention to increase the cAMP concentration in all cell- and tissue-based samples.

[0051] For this purpose, the coumarin-caged forskolin derivative can advantageously be introduced into a cell, and, after irradiation, the increase in the intracellular cAMP concentration, which results from the binding of the biologically active forskolin carbamate 10 to peripheral membrane adenylyl cyclases which are endogenously present in the cells, is measured with a fluorescence-based sensitive detection process.

Exemplary Embodiment

[0052] Embodiments of the invention are explained in more detail below with reference to a synthesis route for the coumarin-caged forskolin derivative 1 and the accompanying figures, without this being intended to limit the invention.

[0053] The following is shown:

[0054] FIG. 1 shows forskolin and NKH 477.

[0055] JCF 1 as coumarin-caged forskolin derivative is synthesized in a 6-step synthesis starting from protected forskolin 2 and a coumarin derivative 3 functionalized with N-methylethylenediamine (FIG. 2). The six synthesis steps (FIG. 3 to FIG. 8) and the synthesis products with reference signs 1, 3, 4, 7, 8 and 9 mentioned therein are not previously known from the literature. Their total yield is 5% relative to the carbonate 6.

Synthesis

[0056] (6-Bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl methyl(2-(2,2,2-trifluoroacetamido)ethyl)carbamate 4 (FIG. 3).

[0057] 2,2,2-Trifluoro-N-(2-methylamino-ethyl)-acetamidel.sup.10,11 5 (536 mg, 3.15 mmol) and 6-bromo-7-methoxymethoxy coumarin-4-ylmethyl 4′-nitrophenyl carbonate.sup.12 6 (1000 mg, 2.09 mmol) are stirred at room temperature (RD for 16 h in 15 mL DMF. The solvent is removed on the rotary evaporator under reduced pressure. The crude product is purified by column chromatography (eluent EE:nHex=7:3).

[0058] This results in (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl methyl(2-(2,2,2-trifluoroacetamido)ethyl)carbamate 4 (850 mg, 1.67 mmol, 80%) as colorless crystals.

MS (ESI+) m/z: [M].sup.+ theor. 511.0; exp. 510.9.
(6-Bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-methyl (2-aminoethyl)methyl)carbamate 3 (FIG. 4).

[0059] Trifluorocarbamate 4 (200 mg, 0.39 mmol) is treated with 25 mL MeOH and 25 mL NaOH.sub.aq (0.1 mol/L) in an ultrasonic bath at room temperature for 2 h. The solution is neutralized with HCl.sub.aq (0.1 mol/L) and then extracted with CH.sub.2Cl.sub.2 (3×50 mL). The combined organic phases are concentrated on the rotary evaporator under reduced pressure. The crude product is purified using column chromatography (eluent CH.sub.2Cl.sub.2:MeOH=9:1).

[0060] This results in (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-aminoethyl)(methyl)carbamate 3 (91 mg, 0.22 mmol, 58%) as colorless crystals.

MS (ESI+) m/z: [M].sup.+ theor. 417.0; exp. 417.0.
(6-Bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-(((((2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-6-(dimethylamino)-12-hydroxy-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyranol[3′,2′:1,2]naphthol[1,8-de][1,3]dioxin-11-Yl)oxy)carbonyl)amino)ethyl)(methyl)carbamate 7 (FIG. 5)

[0061] Pyridine hydrochloride (8.4 mg, 0.073 mmol) and then diazabicycloundecene (DBU, 1.386 mL, 8.9 μmol) are added dropwise to a solution of 7-deacetyl forskolin-6,7-carbonate 1,9-dimethylformamide dimethyl acetal 2 (148 mg, 0.33 mmol) and carbamate 3 (296 mg, 0.72 mmol) in 8 mL pyridine at 0° C. The reaction solution is stirred at 4° C. with the exclusion of daylight in the refrigerator for 5 days. 50 mL CH.sub.2Cl.sub.2 and 10 mL HCl.sub.aq (0.1 mol/L) are added. The organic phase is separated out and concentrated on the rotary evaporator under reduced pressure. The crude product is purified using column chromatography (eluent CH.sub.2Cl.sub.2:MeOH=9:1).

[0062] This results in (6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methyl (2-(((((2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-6-(dimethylamino)-12-hydroxy-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-11-yl)oxy)carbonyl)amino)ethyl)(methyl)carbamate 7 (250 mg, 0.29 mmol, 88%) as colorless crystals.

MS (ESI+) m/z: [M].sup.+ theor. 866.3; exp. 866.3.
(2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-11-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-6-(dimethylamino)-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-12-yl acetate 8 (FIG. 6)

[0063] A solution of the alcohol 7 (150 mg, 170 μmol) in 1.5 mL pyridine and 1.5 mL acetic anhydride is stirred at 4° C. excluding daylight in the refrigerator for 2 days. After the addition of 20 mL H.sub.2O, extraction is carried out using CH.sub.2Cl.sub.2 (3×20 mL). The combined organic phases are washed with saturated NaCl solution and dried with Na.sub.2SO.sub.4. The organic phase is separated out and concentrated on the rotary evaporator under reduced pressure. The crude product is purified using column chromatography (eluent CH.sub.2Cl.sub.2:MeOH=9:1).

[0064] This results in (2R,4aR,4a1R,6S,10aS,11S,12S,12aR)-11-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-6-(dimethylamino)-2,4a1,10,10,12a-pentamethyl-4-oxo-2-vinyldecahydro-2H,8H-pyrano[3′,2′:1,2]naphtho[1,8-de][1,3]dioxin-12-yl acetate 8 (61 mg, 67.4 μmol, 40%) as a colorless foam.

MS (ESI+) m/z: [M].sup.+ theor. 908.3; exp. 908.3.
(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate 9 (FIG. 7).

[0065] A solution of the acetal 8 (208 mg, 0.23 mmol) in 3.6 mL MeOH and 2.4 mL glacial acetic acid is stirred overnight at room temperature. 5 mL saturated Na.sub.2CO.sub.3 solution are added, and the aqueous phase is extracted with CH.sub.2Cl.sub.2 (3×10 mL). The combined organic phases are concentrated on the rotary evaporator under reduced pressure. The crude product is purified using column chromatography (eluent CHCl.sub.3:EE=1:1).

[0066] This results in (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-(((((6-bromo-7-(methoxymethoxy)-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate 9 (95 mg, 0.11 mmol, 48%) as colorless crystals.

MS (ESI+) m/z: [M].sup.+ theor. 853.3; exp. 853.2.
(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2((((6-bromo-7-hydroxy-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-ylacetate (JCF 1, FIG. 8)

[0067] Activated, hot NaHSO.sub.4*SiO.sub.2.sup.13 (100 mg, 0.56 mmol) is added to a solution of the MOM ether 9 (45 mg, 55 μmol) in 5 mL CH.sub.2Cl.sub.2. The catalyst is activated at 120° C. for 48 hours prior to use. The mixture is stirred at room temperature for 16 h and subsequently filtered. The filtrate is washed with CH.sub.2Cl.sub.2 (2×5 mL). The combined organic phases are concentrated on the rotary evaporator under reduced pressure. The crude product is purified using column chromatography (eluent CHCl.sub.3:EE=1:1).

[0068] This results in (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6-(((2-((((6-bromo-7-hydroxy-2-oxo-2H-chromen-4-yl)methoxy)carbonyl)(methyl)amino)ethyl)carbamoyl)oxy)-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate (JCF 1) (29 mg, 36 μmol, 66%) as colorless crystals.

MS (ESI+) m/z: [M+H].sup.+ theor. 809.2; exp. 809.2.

Photolysis

[0069] JCF 1 (or its analogs) can be cleaved to form the desired forskolin carbamate 10 under irradiation with light (FIG. 9 and FIG. 10) and thus qualifies for the aforementioned biological use.

[0070] The photolysis of JCF 1 is carried out under controlled conditions in order to quantitatively detect the release of forskolin carbamate 10 as a function of the amount of light absorbed: 0.16 ml of a 100 μM solution of JCF 1 in MeOH is added to a quartz glass cuvette (width: 4 mm; depth (optical path): 10 mm->fill level 4 mm). The “Intensilight” light source (excitation lamp of a Nikon TI Eclipse fluorescence microscope) is used as the excitation source, the light of which is guided through a gel light guide (active diameter: 4 mm) and a narrowband bandpass filter (368.8 nm±5 nm) onto the liquid column in the cuvette. 1.58 mW was selected as the excitation power (position 32 (32 times attenuation) on the control unit of the excitation lamp). This results in an irradiance of approximately 12.5 mW/cm.sup.2. Irradiation was carried out at time intervals of 1 to 500 seconds by manually opening and closing the closure.

[0071] The irradiated samples are then examined using mass spectrometry (mass spectrometer: MSQ Plus from ThermoScientific; ionization: ESI-interface with a cone voltage of 50 V, eluent: methanol, water, glacial acetic acid, /50, 50, 0.02/vol, vol, vol; flow rate 0.2 ml/min; direct injections of 20 μl of the respective irradiated samples via a Rheodyne injection valve (7725i)). The mass trace m/z 511 and the mass range m/z 807-811 are recorded. The integrals of the peaks of the chromatogram of the mass trace m/z 511 (see FIG. 10) are evaluated. With an exposure time of 320 seconds, no more signals can be detected in the mass range m/z 807-811 (starting compound), and therefore a complete conversion can be assumed after this time under the above-described conditions.

[0072] The reaction can also be carried out analogously with the analogs of JCF-1 prepared according to further embodiments of the invention.

Validation

[0073] The substance JCF 1 described according to embodiments of the invention was validated on eukaryotic cell cultures in which the increase in the intracellular cAMP concentration, which results from the binding of the biologically active forskolin carbamate 10 (FIG. 9) to peripheral membrane adenylyl cyclases which are endogenously present in the cells, using a fluorescence-based sensitive detection process..sup.14 In this regard, a cell line was used in which a cyclic-nucleotide-gated (CNG) ion channel is constitutively expressed. These channels are typically expressed in olfactory sensory neurons of the olfactory epithelium and open when the intracellular cAMP concentration increases. Cations, inter alia Ca.sup.2+ ions, flow through the channel into the cell. The inflow of Ca.sup.2+ can be detected with Ca.sup.2+-sensitive dyes or genetically encoded Ca.sup.2+ indicators, such as GCaMP sensors, in a fluorescence reader or with a fluorescence microscope. In order to detect the Ca.sup.2+ signals, a cell line was prepared which, in addition to the above-mentioned CNG channel additionally constitutively expresses the genetically encoded Ca.sup.2+ indicator GCaMP3.0 (Tian et al., 2009)..sup.15 The GCaMP3.0 protein consists of a circularly permuted EGFP (enhanced green fluorescent protein) to which a binding peptide for calmodulin consisting of myosin light-chain kinase (M13 peptide) is fused N-terminally and a calmodulin is fused C-terminally. At low intracellular Ca.sup.2+ concentrations, GCaMP3.0 does not emit fluorescence. As the intracellular Ca.sup.2+ concentration increases, Ca.sup.2+ ions bind to the calmodulin. This then interacts with the M13 peptide, and a conformational change of the whole protein results. In this form, GCaMP3.0 fluoresces at 510 nm after irradiation with a wavelength of 480 nm. The Ca.sup.2+-dependent change in the fluorescence change can be detected and quantified with the aforementioned processes.

[0074] Cells of the cell line described were seeded in 96-well multi-well plates (MWP) and increased to a density of approximately 25,000. The medium was removed and exchanged with extracellular solution containing 100 μM IBMX (isobutylmethylxanthine) for the inhibition of cell-endogenous phosphodiesterases. The basal fluorescence in the wells of 96-well MWP was then measured with a fluorescence reader. Cells in four wells were loaded with JCF 1 (10 μM and 30 μM) for 30 min at room temperature in the dark. The basal fluorescence in the wells was then measured again before the entire 96-well MWP plate was exposed to light using a UV lamp device (FIG. 11, FIG. 12). After the exposure, 10 μM and 30 μM NKH 477 were each pipetted into four independent wells, and the fluorescence changes in the fluorescence reader were measured (FIG. 13, FIG. 14). Cells that had been incubated only with the extracellular solution (with IBMX) were used as negative control (FIG. 15). It was found that the release of forskolin carbamate 10 from the cage compound JCF-1 by UV exposure results in a significant increase in the Ca.sup.2+-dependent fluorescence emission. Under these conditions, the change in fluorescence reached approximately 50% of the values which were achieved by adding the non-caged NKH 477. No change in Ca.sup.2+-dependent fluorescence emission was measured in cells that had not been incubated with JCF-1 or with NKH 477 (without cage group).

[0075] The use of JCF 1 is universally suitable for all cell- and tissue-based samples in which the intracellular cAMP concentration is to be increased. The possibility of activating the biologically active compound at defined points in time and within the cell by, for example, local release by means of punctiform exposure to light has great advantages over conventional strategies in which an increase in the intracellular cAMP concentration takes place, e.g., via GPCR signaling pathways, via the stimulation of adenylyl cyclases using, for example, NKH 477, or the inhibition of cell-endogenous phosphodiesterases, which hydrolyze the cAMP to AMP, e.g., via IBMX. In the latter processes, changes in the cAMP concentration always occur in the entire cell or within the cell group or tissue group. Moreover, the use of the biologically inactive compound 1 allows the kinetics of cellular processes controlled by increasing the intracellular cAMP concentration to be detected with high time resolution in the sub-second range.

[0076] While the invention has been illustrated and described in detail in the drawings and foregoing description, such illustration and description are to be considered illustrative or exemplary and not restrictive. It will be understood that changes and modifications may be made by those of ordinary skill within the scope of the following claims. In particular, the present invention covers further embodiments with any combination of features from different embodiments described above and below. Additionally, statements made herein characterizing the invention refer to an embodiment of the invention and not necessarily all embodiments.

[0077] The terms used in the claims should be construed to have the broadest reasonable interpretation consistent with the foregoing description. For example, the use of the article “a” or “the” in introducing an element should not be interpreted as being exclusive of a plurality of elements. Likewise, the recitation of “or” should be interpreted as being inclusive, such that the recitation of “A or B” is not exclusive of “A and B,” unless it is clear from the context or the foregoing description that only one of A and B is intended. Further, the recitation of “at least one of A, B and C” should be interpreted as one or more of a group of elements consisting of A, B and C, and should not be interpreted as requiring at least one of each of the listed elements A, B and C, regardless of whether A, B and C are related as categories or otherwise. Moreover, the recitation of “A, B and/or C” or “at least one of A, B or C” should be interpreted as including any singular entity from the listed elements, e.g., A, any subset from the listed elements, e.g., A and B, or the entire list of elements A, B and C.

LITERATURE

[0078] .sup.1 Ellis-Davies G C R.; Nat. Methods 2007, 4, 619-628. [0079] .sup.2 Adams S R., Tsien R Y.; Annu. Rev. Physiol. 1993, 55, 755-784. [0080] .sup.3 Chaulk S G., MacMillan A M.; Nucleic Acids Res. 1998, 26, 3173-3178. [0081] .sup.4 Takeuchi K., Takehara K., Kato S., Yagi K.; Am. J. Physiol. 1997, 272, 646-653. [0082] .sup.5 Kamenetsky M., Middelhaufe S., Bank E M., Levin L R., Buck J., Steegborn C.; J. Mol. Biol. 2006, 362, 623-639. [0083] .sup.6 Mori M., Takeuchi M., Takaoka H., Hata K., Hayashi Y., Yokoyama M.; J. Cardiovasc. Pharmacol. 1994, 24, 310-316. [0084] .sup.7 Laurenza A., Khandelwal Y., De Souza N J., Rupp R H., Metzger H., Seamon K B.; Mol. Pharmacol. 1987, 32, 133-139. [0085] .sup.8 Lai B., Gangopadhyay A K., Gidwani R M., Rajagopalan R., Ghate A V.; Indian J. Chem. 2006, 458, 232-246. [0086] .sup.9 Hartzell H C., Budnitz D., Mol. Pharmacol. 1992, 41, 880-888. [0087] .sup.10 PHARMACOFORE, INC; Jenkins T E., Seroogy J D., Wray J W.; Tong C C.; WO 2011/133178. [0088] .sup.11 Shawe T T., Hepler L P., Chong A M., Fulmer J N., Hansen D B., Watkims J L; Synth. Commun. 1996, 26, 3633-3636. [0089] .sup.12 Fomina N., McFearin C L., Sermsakdi M., Morachis J M., Almutairi A.; Macromolecules 2011, 44, 8590-8597. [0090] .sup.13 Ramesh C., Ravindranath N., Das B.; J. Org. Chem. 2003, 68, 7101-7103. [0091] .sup.14 Balfanz S., Ehling P., Wachten S., Jordan N., Erber J., Mujagic S. and Baumam, A.; Insect Biochem. Mol. Biol. 2012, 42, 435-445. [0092] .sup.15 Tian L., Hires S. A., Mao T., Huber D., Chiappe M. E., Chalasani S. H., Petreanu L., Akerboom J., McKimey S. A., Schreiter E. R., Bargmam C. I., Jayaraman V., Svoboda K., and Looger L. L.; Nat. Meth. 2009, 6, 875-881.